⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11189738 | 0.98 | TSHR (0.33) | — | |
| SCHEMBL538571 | 0.75 | — | — | |
| SCHEMBL2512414 | 0.75 | ACHE (0.38) | — | |
| SCHEMBL3713946 | 0.75 | — | — | |
| SCHEMBL31227385 | 0.75 | — | — | |
| SCHEMBL11916708 | 0.73 | — | — | |
| SCHEMBL11314107 | 0.71 | — | — | |
| SCHEMBL10531382 | 0.71 | — | — | |
| SCHEMBL7063569 | 0.71 | — | — | |
| SCHEMBL1665166 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004163-B | Method for catalyzing vitamin A isomerization by ruthenium catalyst | 万华化学集团股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-111004163-A | Method for catalyzing vitamin A isomerization by ruthenium catalyst | 万华化学集团股份有限公司 | 2020-04-14 | — | — | CN | disclosed |
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & COMPANHIA, S.A. (PT) | 2017-12-21 | — | — | US | disclosed |
| US-9550759-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2017-01-24 | — | — | US | disclosed |
| CN-102781940-B | Substituted imidazopyridyl-aminopyridine compounds | 艾科尔公司 | 2016-09-07 | — | — | CN | disclosed |
| US-20160058768-A1 | SUBSTITUTED AMIDE COMPOUNDS | PFIZER (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2986599-A1 | N-PIPERIDIN-3-YLBENZAMIDE DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | Pfizer Inc. (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9227956-B2 | Substituted amide compounds | PFIZER INC. (US) | 2016-01-05 | — | — | US | disclosed |
| CN-105143203-A | N-piperidin-3-ylbenzamide derivatives for the treatment of cardiovascular diseases | PFIZER | 2015-12-09 | — | — | CN | disclosed |
| EP-1907382-B1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2015-05-27 | — | — | EP | disclosed |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20050272764-A1 | Imidazopyridine compound | EISAI CO., LTD. | 2005-12-08 | — | — | US | disclosed |
| WO-2005103049-A1 | IMIDAZOPYRIDINE COMPOUND | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | WO | disclosed |
| WO-2003037866-A1 | ANTIRETROVIRAL PYRIDINE AND QUINOLINE DERIVATIVES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-6498254-B1 | Antiretroviral compounds and compositions | UNIROYAL CHEMICAL COMPANY, INC. | 2002-12-24 | — | — | US | disclosed |
| US-4585871-A | Process for oxidizing halopyridines to halopyridine-N-oxides | OLIN CORPORATION (US) | 1986-04-29 | — | — | US | disclosed |
| US-4504667-A | Process for oxidizing halopyridines to halopyridine-N-oxides | OLIN CORPORATION (US) | 1985-03-12 | — | — | US | disclosed |
| EP-0130333-A1 | Process for oxidizing halopyridines to halopyridine-N-oxides | OLIN CORPORATION (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0090177-A1 | Process for oxidizing halopyridines to halopyridine-N-oxides | OLIN CORPORATION (US) | 1983-10-05 | — | — | EP | disclosed |
| US-4394155-A | 2-SULFINYL OR 2-SULFONYL SUBSTITUTED | UNIROYAL, INC. (US) | 1983-07-19 | — | — | US | disclosed |